{"url_path":"/sec/imrx/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1790340/0001790340-26-000057-index.html","accession_number":"0001790340-26-000057","cik":"0001790340","ticker":"IMRX","issuer_name":"Immuneering Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1790340/0001790340-26-000057-index.html","primary_entity_key":"0001790340","primary_entity_name":"Immuneering Corp"},"word_count":91,"has_tables":true,"body_markdown":"Item 5. Other Information\n\n(a) Disclosure in lieu of reporting on a Current Report on Form 8-K.\n\nNone.\n\n(b) Material changes to the procedures by which security holders may recommend nominees to the board of directors.\n\nNone.\n\n(c) Insider Trading Arrangements and Policies\n\nDuring the three months ended March 31, 2026, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408(a) of Regulation S-K."}